53 completed, 15 terminated, 4 active not recruiting, 4 recruiting. 83 Phase 1, 16 Phase 2.
Follow Leukemia, Hairy Cell: new trials by email Literature Review of Leukemia, Hairy Cell trials Research Report on Leukemia, Hairy Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | Luminary Therapeutics | 27 | 2026-09-01 | 2026-07-01 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Recruiting | Stanford University | 148 | 2024-03-29 | 2026-08-12 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | MacroGenics | 130 | 2022-07-13 | 2026-07-28 |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant CD22CART cell infusion - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 27 | 2022-05-23 | 2026-10-16 |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. LP-168 - CLL/SLL, Waldenstrom Macroglobulinemia | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 60 | 2021-07-19 | 2026-02-13 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions Trazodone HCl - new polymer, Trazodone HCl - Contramid® - Healthy | Phase 1 | Completed | Aziende Chimiche Riunite Angelini Francesco S.p.A | 28 | 2020-02-17 | 2021-11-29 |
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience - Hairy Cell Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2019-10-03 | 2026-06-29 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies XmAb13676 - B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Xencor, Inc. | 154 | 2016-10-01 | 2024-11-13 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Dasatinib - Non-Hodgkin's Lymphoma, Multiple | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 8 | 2015-02-12 | 2020-03-16 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies AGS67E - Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 71 | 2014-10-14 | 2024-11-01 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. PLX8394 - Melanoma, Thyroid Cancer | Phase 1 | Terminated | Fore Biotherapeutics | 5 | 2014-02-01 | 2020-10-19 |
Showing 20 of 83. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (70) · Lymphoma, Follicular (67) · Lymphoma, Mantle-Cell (67) · Lymphoma, B-Cell, Marginal Zone (64) · Burkitt Lymphoma (61) · Lymphoma, Large B-Cell, Diffuse (59) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (58) · Lymphoma, Non-Hodgkin (57) · Waldenstrom Macroglobulinemia (54) · Lymphoma, Large-Cell, Immunoblastic (51) · Hodgkin Disease (47) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (43) · Lymphoma, T-Cell, Cutaneous (42) · Multiple Myeloma (42)
Hematologic Diseases (83) · Hemic and Lymphatic Diseases (83) · Immune System Diseases (83) · Immunoproliferative Disorders (83) · Lymphatic Diseases (83) · Neoplasms by Histologic Type (83) · Lymphoproliferative Disorders (81) · Neoplasms (78) · Disease Attributes (75) · Pathologic Processes (75) · Pathological Conditions, Signs and Symptoms (75) · Chronic Disease (72) · Leukemia, Lymphoid (72) · Leukemia, B-Cell (70) · Lymphoma, B-Cell (67)
Rituximab (8) · Peripheral Blood Stem Cell Transplantation (7) · fludarabine phosphate (6) · Etoposide (5) · Cyclophosphamide (4) · Filgrastim (4) · Bendamustine Hydrochloride (3) · Bortezomib (3) · Carboplatin (3) · Cyclosporine (3) · Dasatinib (3) · Lenalidomide (3) · Tacrolimus (3) · Vorinostat (3) · Whole-Body Irradiation (3)
National Cancer Institute (NCI) (20) · Fred Hutchinson Cancer Center (5) · City of Hope Medical Center (4) · Memorial Sloan Kettering Cancer Center (4) · Northwestern University (3) · Asan Medical Center (2) · Barbara Ann Karmanos Cancer Institute (2) · Indiana University (2) · Mayo Clinic (2) · Stanford University (2) · University of Medicine and Dentistry of New Jersey (2) · Acerta Pharma BV (1) · Alexey Danilov, MD (1) · Alliance for Clinical Trials in Oncology (1) · Astellas Pharma Global Development, Inc. (1)
United States (78) · Canada (3) · South Korea (3) · Italy (2) · Poland (2) · United Kingdom (2) · France (1) · Germany (1) · Switzerland (1)
Abhinav Deol, M.D. (2) · Kenneth G. Lucas, MD (2) · Kyoo H. Lee, MD (2) · Richard K. Burt, MD (2) · Robert J Kreitman, M.D. (2) · Robert Kreitman, MD (2) · Roger Strair, MD, PhD (2) · Tanya Siddiqi (2) · William K. Kelly, DO (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Alex A. Adjei, MD, PhD (1) · Alex Shalaurov, MD, PhD (1)
PMID 32499241, PMID 41980020, PMID 10552943, PMID 10764422, PMID 11474661, PMID 17020988, PMID 18327587, PMID 18596230, PMID 21745173, PMID 22259028, PMID 22355053, PMID 23393050, PMID 24474568, PMID 24530972, PMID 26853648, PMID 27118452, PMID 28314788, PMID 29292843, PMID 29487070, PMID 30562587, PMID 31617432, PMID 34196037, PMID 34492703, PMID 34515338, PMID 35622074
P30CA015083 (3), P30CA015704 (3), P30CA033572 (3), U01CA097452 (3), P30CA072720 (2), U01CA062505 (2), U01CA069912 (2), U01CA076576 (2), U01CA121947 (2), P01CA018029 (1), P01CA044991 (1), P01CA078902 (1), P30CA006973 (1), P30CA008748 (1), P30CA012197 (1)